Drugs / ASC61
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05287399 | Aug 2022 → Jan 2025 | cancer | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-17 | Ascletis Pharmaceuticals Co., Ltd. | Regulatory Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA ascletis.com ↗
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for the in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-17 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA ascletis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC61 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05287399 ↗ |
| Action | Inhibit | “small-molecule inhibitor of PD-L1” NCT05287399 ↗ |
| Modality | Small molecule | “an orally bioavailable small-molecule inhibitor” NCT05287399 ↗ |
| Route | Oral | “200mg of ASC61 orally once daily for cycles of 28 days” NCT05287399 ↗ |